Episodes

  • 2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth

    2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth
    Feb 3 2025
    In this exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest human challenge trial contract with Inhalon Biopharma, testing a next-generation mucosal RSV antiviral. Mo addresses industry speculation around RSV trials, explains why RSV antivirals remain a key growth area, and shares insights on hVIVO’s strong sales pipeline conversion, with this being their fourth new study announcement in under two months. He also provides a quick update on the recent CRS acquisition and what’s next for the company.
    Show more Show less
    9 mins
  • 2031: Q&A with Oncimmune CEO, Martin Gouldstone

    2031: Q&A with Oncimmune CEO, Martin Gouldstone
    Jan 31 2025
    Watch on YouTube

    After this morning's trading update, CEO Martin Gouldstone of Oncimmune - a leading life sciences firm providing autoantibody profiling services to the Biopharma industry – takes me through the company's current demand picture, pipeline and August FY25 guidance.
    Show more Show less
    9 mins
  • 2030: The Exchange with Richard Staveley of Harwood Capital

    2030: The Exchange with Richard Staveley of Harwood Capital
    Jan 31 2025
    Watch on YouTube

    In this week’s Exchange, accomplished UK fund manager Richard Staveley of Harwood Capital, who runs the Rockwood Strategic investment trust, takes me through his latest thoughts on the following:

    00:00 Secret sauce behind Rockwood’s success.
    06:40 Capita
    13:35 Filtronic & how to value the stock
    19:05 Funding Circle
    24:00 Vanquis Banking
    32:55 Argentex
    38:50 RM
    43:00 Van Elle
    47:25 Flowtech Fluidpower
    52:25 James Fisher
    56:30 STV Group
    1:0:55 Kooth
    1:06:25 Pennant International
    1:10:35 Favourite stock idea for 2025 & portfolio management
    Show more Show less
    1 hr and 14 mins
  • 2029: Q&A with Paul Barrett from Rome Resources

    2029: Q&A with Paul Barrett from Rome Resources
    Jan 31 2025
    Watch on YouTube

    More drilling news from Rome Resources, this time at Kalayi. Paul Barrett joins us to explain the significance of the latest results, what it all means, and what will happen next
    Show more Show less
    9 mins
  • 2028: Q&A with hVIVO CEO, Mo Khan

    2028: Q&A with hVIVO CEO, Mo Khan
    Jan 29 2025
    Exciting times for the company as we sit down with Mo to discuss a record-breaking FY24, the game-changing acquisition of two clinical research units from CRS, and the strategic vision driving future growth. Mo shares insights on the synergies behind the CRS deal, the growing order book, and the evolving £40m pipeline of opportunities. Plus, we explore what’s next for the company’s M&A strategy. Don’t miss this deep dive into a company on the rise!”
    Show more Show less
    12 mins
  • 2027: Q&A with Eleco CEO Jonathan Hunter and CFO Neil Pritchard

    2027: Q&A with Eleco CEO Jonathan Hunter and CFO Neil Pritchard
    Jan 28 2025
    Watch on YouTube

    Following today’s positive FY'24 trading update, CEO Jonathan Hunter and CFO Neil Pritchard of Eleco #ELCO kindly take me through the:

    00:00 Current demand picture & recent client wins for Eleco’s Buildtech software.
    05:20 Financial highlights
    10:10 Strategic rationale & integration of Jan’s €8.4m acquisition of PMI Software
    13:50 Outlook for 2025 and beyond.
    Disclosure: I own shares in Eleco, who is also a Vox Markets client
    Show more Show less
    19 mins
  • 2026: Q&A with Lords Group Trading CEO Shanker Patel & CFO Stuart Kilpatrick

    2026: Q&A with Lords Group Trading CEO Shanker Patel & CFO Stuart Kilpatrick
    Jan 28 2025
    Watch on YouTube

    Following today’s resilient FY'24 trading update, CEO Shanker Patel & CFO Stuart Kilpatrick of Lords Group Trading - a specialist UK builders merchant & heating/plumbing products distributor – take me through the :

    • State of the UK building products market & timing of recovery.
    • Financial highlights & outlook for 2025.
    • Why investors should remain optimistic.
    Show more Show less
    20 mins
  • 2025: Addressing the Rising Threat of Whooping Cough

    2025: Addressing the Rising Threat of Whooping Cough
    Jan 27 2025
    Watch on YouTube

    In an exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest milestone—a world-first pivotal Phase 3 human challenge trial for a whooping cough (pertussis) vaccine candidate. Mo delves into why ILiAD is leading this groundbreaking initiative, the trial’s key objectives, and its significance for hVIVO’s expanding portfolio. He also provides insight into the increasing global burden of pertussis and hVIVO’s readiness to conduct bacterial challenge trials at its state-of-the-art Canary Wharf facility.
    Show more Show less
    7 mins